Valneva: commercial partnership with VBI Vaccines
(CercleFinance.com) - Valneva and VBI Vaccines announce a partnership for the marketing and distribution in several European countries of PreHevbri, the only triple antigen (recombinant and adsorbed) hepatitis B vaccine which is licensed in Europe.
Under the agreement, Valneva will promote and distribute PreHevbri in several European countries, including the UK, Sweden, Norway, Denmark, Finland, Belgium and the Netherlands, with availability in these countries expected in early 2023.
Valneva says PreHevbri was approved by the European Commission (EC) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Q2 2022.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Under the agreement, Valneva will promote and distribute PreHevbri in several European countries, including the UK, Sweden, Norway, Denmark, Finland, Belgium and the Netherlands, with availability in these countries expected in early 2023.
Valneva says PreHevbri was approved by the European Commission (EC) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Q2 2022.
Copyright (c) 2022 CercleFinance.com. All rights reserved.